SCHEMBL5051297

SCHEMBL5051297

C=CCC(C(CCC(=O)O)C(=O)O)P(=O)(O)CCc1ccc2ccccc2c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.45
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
PDPK1 O15530 1/20 0.38
FFAR1 O14842 1/20 0.38
HCAR2 Q8TDS4 1/20 0.37
MME P08473 1/20 0.36
SLC13A5 Q86YT5 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
SOX18 P35713 1/20 0.35
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
MC4R P32245 1/20 0.35
MC5R P33032 1/20 0.35
MC1R Q01726 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5060141 0.78 CYP1A2 (0.49) CYP1A2HDAC1HDAC8HCAR2MME
SCHEMBL5051294 0.78 HDAC1 (0.37) CYP1A2HDAC1HDAC8CYP2C19
SCHEMBL23881672 0.77 CYP1A2 (0.55) CYP1A2HDAC1HDAC8PDPK1FFAR1
SCHEMBL5057892 0.75 CYP1A2 (0.47) CYP1A2FFAR1MMENR1H4MC4R
SCHEMBL5059863 0.74 FOLH1 (0.38) FFAR1CYP2C19
SCHEMBL5052929 0.73 CYP2D6 (0.46) HDAC1HDAC8CYP2D6
SCHEMBL7931943 0.73 CYP1A2 (0.46) CYP1A2FFAR1MMENR1H4MC4R
SCHEMBL5060436 0.73 CYP1A2 (0.52) CYP1A2
SCHEMBL5054192 0.72 CYP1A2 (0.51) CYP1A2HDAC1HDAC8PDPK1FFAR1
SCHEMBL5053125 0.72 GGH (0.53) CYP1A2HDAC1HDAC8FFAR1MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0994707-A4 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARM INC (US) 2001-11-14 EP claimed
EP-0994707-A1 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 2000-04-26 EP claimed
WO-1998053812-A1 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1998-12-03 WO claimed
US-20080311037-A1 Compounds which bind PSMA and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2008-12-18 US disclosed
US-6025345-A NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, GUILFORD PHARMACEUTICALS INC. (US) 2000-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311037-A1 Compounds which bind PSMA and uses thereof FOLH1, PSMA1, BPHL CYP1A2 4283/4885HDAC1 525/4885HDAC8 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.